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Abstract 
Background  Epidemiological evidence proposes the direct involvement of the liver 
enzymes in atrial fibrillation. These relationships are controversial and mechanistically 
unclear. As part of the British Regional Heart Study, we investigated whether change in liver 
enzymes over time associates with atrial fibrillation in men initially free of this heart 
condition.  
Materials and Methods  We prospectively investigated change (delta) in liver enzymes and 
new-onset atrial fibrillation in a representative sample of 1428 men aged 60-79 years.   
Results  Mean follow-up was 12.3 years, after which 108 new atrial fibrillation cases were 
identified.  The liver enzymes did not differ at baseline or follow-up, except for gamma-
glutamyl transferase which was higher at follow-up in men who developed atrial fibrillation 
compared to those who did not (P<0.0001).  Change in GGT was greater in men who 
developed AF than those who did not (+6.12 vs. –2.60U/l, P=0.036).  N-terminal pro-brain 
natriuretic peptide (baseline and follow-up, P<0.0001) and total bilirubin (follow-up only, 
P<0.0001) were also higher in men who developed atrial fibrillation while serum 
haemoglobin was similar at baseline and follow-up (P≥0.74). Atrial fibrillation was 
associated with change in gamma-glutamyl transferase (OR, 1.18; 95%CI, 1.01–1.37) after 
multiple adjustments and exclusions.  However, after adjusting for baseline (P=0.088) or 
change (P=0.40) in N-terminal pro-brain natriuretic peptide, the association between atrial 
fibrillation and change in gamma-glutamyl transferase was lost.   
Conclusion  The direct relationship between atrial fibrillation and liver enzymes is absent 
and depends, at least in part, on the progression of heart failure as captured by N-terminal 
pro-brain natriuretic peptide. 
Keywords: Liver enzymes, atrial fibrillation, heart failure 
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Introduction 
The direct involvement of liver enzymes in cardiovascular disease, especially gamma-
glutamyl transferase (GGT) [1], remains controversial [2,3].  Recent population-based 
evidence suggests that circulating liver enzymes also associates independently with atrial 
fibrillation (AF) [4-7].  The evidence on this finding is limited, inconsistent and 
mechanistically unclear.  In the Framingham cohort, associations existed between AF risk 
and alanine transaminase (ALT) and aspartate transaminase (AST) [6], while in the 
Atherosclerosis Risk in Communities study, GGT but not ALT or AST predicted new-onset 
AF [7].  These studies [6,7] mostly accounted for baseline characteristics of participants 
initially free of AF, rendering it difficult to capture and account for the evolving 
pathophysiology.  Heart failure contributes to atrial dysfunction and vice versa [8-11], but 
also increases central- and hepatic venous pressure leading to congestive hepatopathy, 
augmenting circulating GGT, bilirubin and alkaline phosphatase (ALP) levels [12-14].  
However, the relationship between AF and liver enzymes could be more complex as the 
association also exists in the absence of clinically diagnosed heart failure [6].  Currently, no 
evidence is available on the change in liver enzymes over time and new-onset AF.  With the 
incidence of AF projected to more than double by 2030 with significant economic 
implications [15], an understanding of the mechanisms at work has clinical importance.  To 
investigate the relationship between new-onset AF and change in liver enzymes over time, we 
used prospective data from the British Regional Heart Study. 
Materials and Methods 
Reporting of this study conforms to STROBE statement [16]. 
Study population 
The British Regional Heart Study is a prospective cohort study involving 7735 randomly 
selected men from 24 towns representing all major British regions (response rate, 78%) [17].  
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We followed the men since 1978–1980 when they were aged 40-59 years and re-examined 
them at ages 60-79 years (1998–2000) and 71-92 years (2010-2012).  The first re-
examination after 20 years included 4252 men (77% response rate) and the second after 32 
years 1722 men (55% response rate).  For the present investigation, we used the first re-
examination as baseline (1998–2000) and the second (2010-2012) as the follow-up for 
outcome assessment.  All participants gave informed written consent and could withdraw at 
any stage. The protocol complied with the Declaration of Helsinki of 1975 (as revised in 
1983) and all relevant local research ethics committees provided ethical approval.   
Participant examinations and exclusions 
The re-examinations included completion of a questionnaire on lifestyle and medical history, 
a physical examination, a 12-lead electrocardiogram (ECG), and collection of fasting blood 
samples using the Sarstedt Monovette System for biochemical analysis. 
Electrocardiograms were recorded using a Siemens Sicard 460 and transmitted to the 
University of Glasgow ECG core lab for analysis using the University of Glasgow ECG 
interpretation program [18] with an additional model for automated Minnesota Coding [19].  
All reports were carefully reviewed and edited wherever necessary.  Prevalent heart failure at 
baseline and follow-up was based on a doctor-confirmed diagnosis of heart failure from 
medical records and verified by review of available clinical information from primary and 
secondary care records. 
Blood samples were frozen and stored at –20°C on the day of collection and transferred in 
batches for storage at –70°C until analysis, which was carried out after no more than one 
freeze-thaw cycle.  Details of measurement and classification methods for smoking status, 
alcohol intake, blood pressure, and blood lipids in this cohort have previously been described 
[20-22].  C-reactive protein (CRP) was assayed by ultrasensitive nephelometry (Dade 
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Behring, Milton Keynes, United Kingdom) and plasma glucose by a glucose oxidase method 
using a Falcor-600 automated analyzer. Hepatic enzymes including GGT, AST, ALT and 
ALP, as well as serum albumin, total protein and total bilirubin, were measured using a 
Hitachi 747 automated analyzer.  The normal laboratory range was 8 to 61 U/l for GGT, <37 
U/l for AST, <41 U/l for ALT and 35-129 U/l for ALP.  The measurement of baseline and 
follow-up liver enzymes followed the same enzymatic calorimetric assay principle [23-25].  
N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was measured using the 
Elecsys 2010 electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK). 
Statistical analysis 
For database management and statistical analysis, we used SAS software, version 9.4 (SAS 
Institute Inc., Cary, NC).  The distributions of GGT, ALT, AST, ALP, blood glucose, NT-
proBNP, and C-reactive protein were normalized by logarithmic transformation.  We 
compared means and proportions by the standard normal z-test and the 2 statistic, while 
longitudinal changes in means and proportions were assessed by the PROC MIXED 
procedure and McNemar’s test, respectively.  Statistical significance was set at a level of 0.05 
on 2-sided tests.  We analyzed associations with AF using logistic regression analysis to 
calculate odds ratios (OR) standardized to 1 standard deviation (SD) and 95% confidence 
intervals (CI), while allowing for covariates and potential confounders.  We applied the 
forward stepwise procedure with P values for explanatory variables to enter and stay in the 
model set at 0.05.  Covariates included in the model were respective baseline liver enzymes, 
baseline age, body mass index, systolic blood pressure, total cholesterol, serum glucose, 
physical activity, smoking, drinking, use of anti-hypertensive medication, and follow-up 
time.  Physical activity used in the regression models was classified into inactive, occasional, 
light, moderate and vigorous; smoking into never, former and current smokers; and drinking 
into none, occasional, light, moderate, and heavy drinkers. We performed sensitivity analysis 
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by additionally, but separately, adjusting for baseline C-reactive protein, ALT, AST, 
ALT/AST ratio, bilirubin, NT-proBNP and their respective change (∆). We also repeated our 
analysis after excluding participants with GGT outside its reference range (>61 U/l), and 
those who had a previous myocardial infarction or heart failure at baseline or follow-up. 
Lastly, since NT-proBNP levels above 900 pg/ml in people aged 50-75 years is indicative of 
heart failure [26,27], we repeated our analysis in participants who had NT-proBNP levels 
below 900 pg/ml at both baseline and follow-up. 
Results 
Participant characteristics 
We based our study on 1722 men who took part in both the first and second follow-up 
examinations.  We excluded 256 participants without blood measurements at baseline or 
follow-up, 20 with no electrocardiogram measurements at follow-up, and 18 with AF at 
baseline, leaving 1428 participants for inclusion in the analysis.  After a mean follow-up of 
12.3 years (5th to 95th percentile interval, 12.1–12.9 years), 108 new cases of AF were 
identified.  The baseline characteristics of participants who developed or did not develop AF 
are presented in Table 1 and follow-up characteristics in Supplementary Table 1.  Circulating 
levels of AST, ALT and ALP at baseline (P≥0.083) and follow-up (P≥0.054) did not differ 
between men who did or did not develop AF (Supplementary Figure 1).  GGT was also 
similar in both groups at baseline (P=0.93), however GGT at follow-up (P<0.0001, Figure 
1A) and change (∆) in GGT from baseline to follow-up (+6.12 vs. –2.60 U/l, P=0.036) were 
higher in the men with AF at follow-up.  In addition, both NT-proBNP (P<0.0001, Figure 
1B) and total bilirubin (P<0.0001, Figure 1C) at follow-up were higher in the AF group and 
increased more markedly from baseline to follow-up (both P<0.0001), while mean 
haemoglobin did not differ between the groups at both baseline (P=0.82) and follow-up 
(P=0.74, Figure 1D). 
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Self-reported alcohol intake did not differ between the groups at baseline (P=0.55) or 
follow-up (P=0.62) and intake declined from baseline to follow-up in both the AF (P=0.028) 
and non-AF groups (P<0.0001; data not shown).  Similarly, the AST/ALT ratio as a measure 
of alcoholic liver damage did not differ between the groups at baseline (P=0.18) or follow-up 
(P=0.21) and decreased in both groups from baseline to follow-up (with AF, P<0.0001; 
without AF, P<0.0001; data not shown).   
Univariate and multivariate analyses 
In univariate analysis in the total group (Supplementary Table 2), ∆NT-proBNP correlated 
with ∆GGT (r=0.14, P<0.0001), ∆total bilirubin (r=0.13, P<0.0001) and ∆ALP (r=0.10, 
P=0.0001), but not with ∆ALT (r=0.01, P=0.61) or ∆AST (r=0.04, P=0.17).   
In univariate logistic regression analysis (Table 2), none of the liver enzymes at baseline, 
or the change in AST, ALT or ALP was associated with AF.  However a 1-SD increase in 
∆GGT was associated with a 21.7% (95% CI, 5.2–40.6%; P=0.008) increased odds of 
developing AF.  After adjusting for baseline GGT and other covariates and potential 
confounders (Table 2), the above association between AF and ∆GGT remained significant 
(OR, 1.18; 95% CI, 1.01–1.37; P=0.032).  Associations with AST, ALT and ALP (P≥0.14) or 
their change (P≥0.73) remained non-significant. 
Sensitivity analysis 
Additional adjustments (Table 3) for baseline C-reactive protein as a marker of inflammation 
(P=0.018), ALT (P=0.032), AST (P=0.031), the AST/ALT ratio to account for alcoholic liver 
disease (P=0.032), ALP (P=0.032) as well as their respective change from baseline to follow-
up (P≤0.032), did not appreciably affect our findings.  Our results also remained significant 
after excluding those with GGT levels outside the reference range (>61 U/l, P=0.0004), those 
with a previous myocardial infarction (P=0.032), and even after excluding 74 participants 
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with prevalent and incident heart failure (P=0.015).  However, when accounting for baseline 
(P=0.088) or change in NT-proBNP (P=0.40) as a clinical measure of heart failure and left 
ventricular systolic- and diastolic dysfunction, the relationship between AF risk and ∆GGT 
was no longer present.  When adjusting for ∆total bilirubin, statistical significance was also 
lost (P=0.13).  Entering both ∆NT-proBNP and ∆total bilirubin in the model confirmed the 
absence of an independent relationship between AF and ∆GGT (P=0.62).  Lastly, by 
repeating our analysis in participants with NT-proBNP levels below 900 pg/ml at both 
baseline and follow-up, the relationship between AF and ∆GGT was absent (OR, 0.86; 95% 
CI, 0.55–1.33; P=0.50). 
Discussion 
We investigated in a representative sample of older British men initially free of AF, whether 
change in liver enzymes over 12.3 years were associated with new-onset AF.  While no 
evidence existed for baseline liver enzymes, initial findings indicated a seemingly robust 
association between AF and change in GGT after multiple adjustments and exclusions 
including participants with prevalent and incident heart failure.  However, this relationship 
was dependent on the progression of heart failure as represented by change in NT-proBNP. 
The concept of cardiovascular events, and more recently AF relating to liver enzymes has 
become a matter of debate and remains mechanistically unclear [1-7]..  Sinner et al. [6] 
followed 3,744 participants (mean age, 65 years) free of AF and heart failure at baseline and 
found a respective 19% and 12% increased risk of developing new-onset AF per one standard 
deviation increase in baseline ALT and AST.  The authors confirmed these results after 
multiple adjustments including interim heart failure as a dichotomous variable, but not for 
AST after adjusting for C-reactive protein as a marker of systemic inflammation [6].  They 
provided no descriptive data on interim heart failure and incidence was likely higher in the 
AF group that was older by a mean of 6.8 years [6].  In our study population of similar age, 
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no such evidence existed for the liver transaminases, even in univariate analysis and 
including participants with incident heart failure.  Alonso et al. provided the first prospective 
evidence for linking new-onset AF with GGT, but were unable to confirm a relationship with 
ALT or AST in 9,333 men and women aged 53-75 years [7].  This study involved extreme-
case statistical analysis by quintiles of baseline GGT.  The authors did include baseline NT-
proBNP and C-reactive protein in the quintile analysis, and confirmed the results after 
excluding participants with prevalent heart failure at baseline.  However, there were no 
indication whether NT-proBNP was included in the continuous analysis when mentioning a 
20% increased risk of AF per doubling of GGT [7].   
The above studies were limited in their ability to capture the pathophysiological 
progression of disease by accounting only for baseline covariates and potential confounders.  
We were able to show in those who developed AF, that a greater increase in GGT was 
paralleled by NT-proBNP and bilirubin as respective sensitive markers of progressive heart 
failure [28] and congestive hepatopathy [29].  In heart failure patients, elevated liver function 
tests are a consequence of either backward failure, increasing central venous pressure; or 
forward failure with attenuated cardiac output and consequent liver perfusion [12-14,30].   
Decreased liver perfusion elevates the transaminases due to hepatocellular damage 
[14,29,31], while increased central venous pressure transmits to the hepatic veins and results 
in elevations in GGT, bilirubin and ALP [32,33].  In our study, GGT and bilirubin, which did 
not differ at baseline between the groups, were higher in those with AF at follow-up, while 
ALP was borderline higher in the AF group at baseline and follow-up.  ALP is normally 
elevated in more extreme cholestatic conditions [34] and it is reasonable to assume that the 
effects of hepatic congestion would firstly be seen for GGT and bilirubin before the 
impediment to bile flow.  Van Deursen et al. [14] reported that abnormalities in all liver 
function tests were associated with invasively-measured central venous pressure.  
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Importantly, higher central venous pressure was predominantly related to GGT and bilirubin 
[14].  From our results, it seems more likely that the backward failure–central venous 
pressure mechanism could explain our findings, especially since the liver transaminases did 
not differ between those with and without AF.  In addition, the positive univariate 
associations in the total group of NT-proBNP with ∆GGT, ∆ALP and ∆total bilirubin, but not 
with ∆ALT or ∆AST, at least in part, supports this pathway. 
The link between AF and ∆GGT was dependent on ∆NT-proBNP, even in the absence of 
diagnosed heart failure, therefore capturing the confounding effect of heart failure at 
subclinical level.  Supporting this was the absence of the AF-∆GGT link when repeating our 
analysis in participants who consistently had NT-proBNP levels below 900 ng/ml (above 
which is indicative of heart failure for people aged 50-75 years) [26,27].  Heart failure and 
AF often coincide with causal pathways in both directions [8-11].  This is at least partly 
supported by our results confirming the known [35,36] relationship between NT-proBNP and 
AF (OR, 1.53; 95% CI, 1.24-1.88; P<0.0001) in fully adjusted models which also included 
∆GGT and ∆total bilirubin.  On balance, the link between the failing heart and the liver 
described above also seems evident with the disappearance of the association between AF 
and GGT after adjusting for ∆total bilirubin as both GGT and bilirubin are elevated in 
congestive hepatopathy [12-14].  Taken together, no direct relationship seems apparent 
between AF and the liver enzymes, which, even in the absence of prevalent and incident heart 
failure, seems due to progression of heart failure leading to both AF and hepatic congestion. 
The current study must be interpreted within the context of its potential limitations. 
Although our cohort is socially representative of older white British men, our results may not 
be generalizable to younger populations, women and other ethnicities.  We investigated 
overall AF only and therefore cannot comment on the associations of the liver enzymes and 
AF type (i.e., valvular, paroxysmal, persistent, or permanent).  The increase in total bilirubin 
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from baseline to follow-up could also be due to augmented bilirubin production (increased 
haemolysis) [37], however this seems unlikely since haemoglobin levels did not differ 
between those with and without AF at both baseline and follow-up.  Although the same 
enzymatic calorimetric assay principle was used to determine the liver enzyme levels at 
baseline and follow-up, the storage time difference of samples could have affected the results. 
However, a similar trend in GGT levels could be seen in participants who passed away 
between after 1998-2000 (not included in the present study) with GGT being higher in those 
with AF compared to those without (Supplementary Figure 2).   
In conclusion, the direct relationship between atrial fibrillation and liver enzymes is absent 
and depends, at least in part, on the progression of heart failure as captured by NT-proBNP. 
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Legend 
Figure 1. Comparison of gamma-glutamyl transferase, N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP), total bilirubin and haemoglobin at baseline and follow-up 
between those with and without atrial fibrillation at follow-up. AF, atrial fibrillation.  
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Values are number of subjects (%), arithmetic mean ± SD, or geometric mean (5th to 95th 
percentile interval). ALT, alanine transaminase; AST, aspartate transaminase; NT-proBNP, 
N-terminal prohormone of brain natriuretic peptide. 
 
Table 1 Baseline characteristics of men with and without atrial fibrillation (AF) at follow-
up 
 
Without AF 
(n=1320) 
With AF  
(n=108) 
P 
Age (years) 66.1 ± 4.6 67.9 ± 5.2 0.001 
Body mass index (kg/m2) 26.6± 3.3 27.2 ± 3.3 0.10 
Systolic blood pressure (mmHg) 145.5 ± 21.8 149.8 ± 24.7 0.12 
Diastolic blood pressure (mmHg) 85.0 ± 10.2 85.3 ± 10.1 0.21 
Gamma-glutamyl transferase (U/l) 27.8 (13.0-80.0) 27.9 (13.0-94.0) 0.93 
Aspartate transaminase (U/l) 23.5 (16.0-35.0) 22.9 (16.0-38.0) 0.36 
Alanine transaminase (U/l) 16.7 (9.0-33.5) 15.6 (8.0-34.0) 0.12 
Alkaline phosphatase (U/l) 78.3 (51.0-119.5) 81.4 (56.0-117.0) 0.083 
ALT:AST 1.48 ± 0.50 1.54 ± 0.54 0.18 
Total bilirubin (µmol/l) 9.11 (4.00-17.00) 9.70 (5.00-18.00) 0.22 
Total protein (g/l) 76.6 ± 4.3 76.4 ± 4.5 0.53 
Serum albumin (g/l) 44.5 ± 2.6 43.7 ± 2.7 0.004 
Blood glucose (mmol/l) 5.74 (4.70-7.40) 5.73 (4.80-7.10) 0.60 
Total cholesterol (mmol/l) 6.09 ± 1.06 6.17 ± 1.09 0.46 
C-reactive protein (mg/l) 1.31 (0.23-8.10) 1.73 (0.33-12.2) 0.013 
NT-proBNP (pg/ml) 63.3 (12.0-344.0) 116.2 (26.0-699.0) <0.0001 
Current smoking n, (%) 97 (7.4) 7 (6.5) 0.70 
Drinking n, (%)   0.55 
None 91 (7.0) 6 (5.7)  
Occasional 334 (25.5) 25 (23.6)  
Light 625 (47.8) 51 (48.1)  
Moderate 230 (17.6) 19 (17.9)  
Heavy 26 (2.0) 5 (4.7)  
Physically inactive n, (%) 66 (5.0) 6 (5.6) 0.80 
Previous myocardial infarction ] 
n, (%) 
117 (8.9) 10 (9.3) 0.70 
Heart failure n, (%) 11 (0.8) 1 (0.9) 0.86 
Anti-hypertensive meds n, (%) 305 (23.4) 33 (30.6) 0.092 
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Table 2 Associations between atrial fibrillation and baseline liver enzyme concentrations and changes in liver 
enzyme concentrations between baseline and follow-up 
 Atrial fibrillation (Odds Ratio, 95%CI) 
Main independent variables Unadjusted +Age Primary model 
Baseline γ-glutamyl transferase (U/l) 1.01 (0.83 – 1.23) 1.04 (0.85 – 1.26) 0.95 (0.77 – 1.18) 
∆ γ-glutamyl transferase (U/l) 1.22 (1.05 – 1.41)† 1.21 (1.04 – 1.40)* 1.18 (1.01 – 1.37)* 
Baseline aspartate transaminase (U/l) 0.89 (0.72 – 1.09) 0.92 (0.75 – 1.12) 0.89 (0.72 – 1.10) 
∆ Aspartate transaminase (U/l) (U/l) 1.09 (0.87 – 1.37) 1.08 (0.86 – 1.35) 0.97 (0.74 – 1.26) 
Baseline alanine transaminase (U/l) 0.84 (0.69 – 1.03) 0.91 (0.74 – 1.12) 0.85 (0.69 – 1.06) 
∆ Alanine transaminase (U/l) 1.05 (0.85 – 1.28) 1.05 (0.85 – 1.30) 1.00 (0.77 – 1.29) 
Baseline alkaline phosphatase (U/l) 0.57 (0.16 – 2.06) 1.13 (0.93 – 1.36) 1.11 (0.92 – 1.35) 
∆ Alkaline phosphatase (U/l) 1.06 (0.88 – 1.26) 1.01 (0.85 – 1.20) 1.00 (0.84 – 1.20) 
Primary model included baseline gamma-glutamyl transferase, age, body mass index, systolic blood pressure, diastolic blood pressure, total 
cholesterol, serum glucose, physical activity, smoking, drinking, use of anti-hypertensive medication, and follow-up time. *, P<0.05; †, P<0.01. 
∆ denotes delta or change from baseline to follow-up. 
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Table 3 Sensitivity analysis for the association between atrial fibrillation and 
gamma-glutamyl transferase 
Atrial fibrillation 
∆ Gamma-glutamyl transferase (U/l) OR (95%CI) P 
Primary model 1.18 (1.01 – 1.37) 0.032 
+ baseline CRP 1.20 (1.03 – 1.40) 0.018 
+ ∆CRP 1.20 (1.03 – 1.39) 0.020 
+ baseline ALT 1.18 (1.01 – 1.37) 0.032 
+ ∆ALT 1.18 (1.01 – 1.37) 0.032 
+ baseline AST 1.18 (1.01 – 1.37) 0.032 
+ ∆AST 1.18 (1.02 – 1.38) 0.031 
+baseline ALP 1.18 (1.01 – 1.37) 0.032 
+ ∆ALP 1.18 (1.01 – 1.37) 0.032 
+ AST/ALT ratio 1.18 (1.01 – 1.37) 0.032 
+ ∆AST/ALT ratio 1.18 (1.02 – 1.38) 0.031 
+ exclude GGT >61 U/l 1.44 (1.18 – 1.76) 0.0004 
+ exclude previous MI 1.18 (1.01 – 1.37) 0.032 
+ exclude HF 1.21 (1.04 – 1.42) 0.015 
+ Baseline bilirubin 1.18 (1.01 – 1.37) 0.032 
+ ∆bilirubin 1.13 (0.97 – 1.32) 0.13 
+ Baseline NT-proBNP 1.15 (0.98 – 1.34) 0.088 
+ ∆NT-proBNP 1.08 (0.91 – 1.28) 0.40 
+ ∆NT-proBNP + ∆ bilirubin 1.05 (0.88 – 1.25) 0.62 
The primary model included baseline gamma-glutamyl transferase, age, body mass index, 
systolic blood pressure, diastolic blood pressure, total cholesterol, serum glucose, physical 
activity, smoking, drinking, use of anti-hypertensive medication, and follow-up time. ALT, 
alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; GGT, gamma-
glutamyl transferase; HF, heart failure; MI, myocardial infarction; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide. ∆ denotes delta or change from baseline to follow-
up. 
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Figure 1. Comparison of gamma-glutamyl transferase, N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP), total bilirubin and haemoglobin at baseline and follow-up 
between those with and without atrial fibrillation at follow-up. AF, atrial fibrillation.  
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Values are number of subjects (%), arithmetic mean ± SD, or geometric mean (5th to 95th 
percentile interval). AF, atrial fibrillation; AST, aspartate transaminase; ALT, alanine 
transaminase; NT-proBNP, N-terminal prohormone of brain natriuretic peptide. 
Supplementary Table 1 Characteristics of men at follow-up with and without atrial fibrillation (AF) 
 
Without AF 
(n=1320) 
With AF  
(n=108) 
P 
Age (years) 78.4 ± 4.6 80.1 ± 5.2 0.001 
Body mass index (kg/m2) 26.9± 3.8 27.4 ± 3.9 0.19 
Systolic blood pressure (mmHg) 146.0 ± 19.2 137.4 ± 20.4 <0.0001 
Diastolic blood pressure (mmHg) 76.2 ± 11.3 79.2 ± 13.6 0.028 
Gamma-glutamyl transferase (U/l) 24.4 (11.0-69.0) 33.2 (14.0-115.0) <0.0001 
Aspartate transaminase (U/l) 22.7 (15.0-35.0) 22.3 (17.0-33.0) 0.33 
Alanine transaminase (U/l) 18.6 (10.0-35.0) 18.4 (11.0-34.0) 0.75 
Alkaline phosphatase (U/l) 69.4 (44.0-109.0) 73.1 (49.0-118.0) 0.054 
ALT:AST 1.27 ± 0.42 1.34 ± 0.45 0.21 
Total bilirubin (µmol/l) 11.05 (6.00-23.00) 13.80 (7.00-28.00) <0.0001 
Total protein (g/l) 70.0 ± 4.1 69.9 ± 4.1 0.80 
Serum albumin (g/l) 44.8 ± 2.4 44.5 ± 2.5 0.15 
Blood glucose (mmol/l) 5.58 (4.60-7.90) 5.83 (4.70-9.00) 0.085 
Total cholesterol (mmol/l) 4.66 ± 1.04 4.39 ± 0.98 0.006 
C-reactive protein (mg/l) 1.30 (0.18-9.82) 1.96 (0.42-14.76) 0.0007 
NT-proBNP (pg/ml) 120 (12-1057) 993 (264-3554) <0.0001 
Current smoking n, (%) 46 (3.5) 1 (0.9) 0.15 
Drinking n, (%)   0.62 
None 141 (10.7) 14 (13.0)  
Occasional 401 (30.4) 34 (31.5)  
Light 542 (41.1) 40 (37.0)  
Moderate 152 (11.5) 17 (15.7)  
Heavy 20 (1.5) 1 (0.01)  
Physically inactive n, (%) 212 (16.1) 21 (19.4) 0.36 
Previous myocardial infarction n, (%) 135 (10.2) 11 (10.2) 0.70 
Heart failure n, (%) 61 (4.6) 13 (12.0) 0.0008 
Anti-hypertensive meds n, (%) 759 (57.5) 83 (76.9) <0.0001 
Supplementary Table 2  Univariate associations between change in NT-
proBNP and liver enzymes concentrations from baseline to follow-up 
 Total group With AF  Without AF 
 ∆NT-proBNP 
 r P r P r P 
∆GGT 0.14 <0.0001 0.15 0.14 0.11 <0.0001 
∆ALT 0.01 0.61 0.02 0.87 0.01 0.72 
∆AST 0.04 0.17 0.02 0.86 0.04 0.20 
∆AST/ALP –0.04 0.19 –0.12 0.24 –0.02 0.43 
∆ALP 0.10 0.0001 0.16 0.10 0.10 0.0005 
∆Bilirubin 0.13 <0.0001 0.15 0.13 0.08 0.004 
NT-proBNP, N-terminal prohormone of brain natriuretic peptide, GGT, gamma-glutamyl 
transferase; ALT, alanine transaminase; AST, aspartate transaminase; ∆ denotes change from 
baseline to follow-up. 
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Supplementary Figure 1 Comparison of aspartate transaminase, alanine transaminase and alanine phosphatase at baseline and follow-up 
between those with and without atrial fibrillation at follow-up. AF. 
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Supplementary Figure 2  Comparison of gamma-glutamyl transferase between those with 
and without atrial fibrillation at the original baseline (1978-1980), first follow-up/current 
baseline (1998-2000) and second follow-up (2010-2012).  The circles represent participants 
with (●) and without (○) atrial fibrillation that passed away after the first follow-up/current 
baseline (1998-2000) and not included in the present study. The diamonds represent the 
participants with (♦) and without (◊) atrial fibrillation included in the current study and alive 
at the second follow-up (2010-2012). 
